adenoviral vector expressing hsv-tk
Biologicalexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02446093)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adenoviral vector expressing hsv-tk
- adv/hsv-tk
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03541928 | Phase 2 | Aug 31, 2018 | Methodist Cancer Center, Houston, Texas |
| NCT03603405 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2018 | Methodist Cancer Center, Houston, Texas |
| NCT03004183 | Phase 2 | Jul 1, 2017 | Merck, Methodist Cancer Center, Houston, Texas |
| NCT02831933 | Phase 2 | Feb 15, 2017 | Cornell University, Methodist Cancer Center, Houston, Texas |
| NCT02446093 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Candel Therapeutics, Ohio State University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 4 | 3 | 1 | 2017 |
| Candel Therapeutics | For profit | 1 | 1 | 1 | 2015 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1